Hepatitis B virus treatment

Details for Australian Patent Application No. 2002247084 (hide)

Owner Nventa Biopharmaceuticals Corporation

Inventors Liu, Hongwei; Siegel, Marvin; Mizzen, Lee

Agent Davies Collison Cave

Pub. Number AU-B-2002247084

PCT Pub. Number WO2002/062959

Priority 60/266,733 05.02.01 US

Filing date 5 February 2002

Wipo publication date 19 August 2002

Acceptance publication date 4 January 2007

International Classifications

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology

A61K 39/29 (2006.01) Medicinal preparations containing antigens or antibodies - Hepatitis virus

A61K 39/385 (2006.01) Medicinal preparations containing antigens or antibodies - Haptens or antigens, bound to carriers

A61K 48/00 (2006.01) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

A61P 31/20 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

C07K 14/02 (2006.01) Peptides having more than 20 amino acids

C07K 14/35 (2006.01) Peptides having more than 20 amino acids

C07K 14/47 (2006.01) Peptides having more than 20 amino acids

C07K 19/00 (2006.01) Hybrid peptides

C12N 1/15 (2006.01) Micro-organisms, e.g. protozoa - modified by introduction of foreign genetic material

C12N 1/19 (2006.01) Micro-organisms, e.g. protozoa - modified by introduction of foreign genetic material

C12N 1/21 (2006.01) Micro-organisms, e.g. protozoa - modified by introduction of foreign genetic material

C12N 5/10 (2006.01) Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

C12N 15/51 (2006.01) Mutation or genetic engineering - Hepatitis viruses

C12N 15/62 (2006.01) Mutation or genetic engineering - DNA sequences coding for fusion proteins

C12P 21/02 (2006.01) Preparation of peptides or proteins - having a known sequence of two or more amino acids, e.g. glutathione

Event Publications

13 February 2003 Application Open to Public Inspection

  Published as AU-B-2002247084

14 December 2006 Change of Name(s) of Applicant(s), Section 104

  StressGen Biotechnologies Corp. The name of the applicant has been changed to Nventa Biopharmaceuticals Corporation

4 January 2007 Application Accepted

  Published as AU-B-2002247084

3 May 2007 Standard Patent Sealed

1 September 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002247085-CELL FUSION ASSAYS FOR THE IDENTIFICATION OF ANTIVIRAL COMPOUNDS, AND SYSTEMS AND KITS FOR PRACTICING THE SAME

2002247083-SYSTEM AND METHOD FOR AMPLIFYING AN ANGLE OF DIVERGENCE OF A SCANNED ION BEAM